Anti-TNFSF4 therapeutic antibody (Pre-made Tavolimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tavolimab (MEDI 0562), a humanised IgG1κ monoclonal antibody agonist of OX40, was being developed by MedImmune for the treatment of solid tumours, including ovarian cancer.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-553-1mg	1mg	3090
GMP-Bios-ab-553-10mg	10mg	21890
GMP-Bios-ab-553-100mg	100mg	148000
GMP-Bios-ab-553-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-TNFSF4 therapeutic antibody (Pre-made Tavolimab biosimilar,Whole mAb)
INN Name	Tavolimab
Target	TNFSF4
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2018
Companies	European Network of Gynaecological Oncological Trial Groups;MedImmune
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Ovarian cancer;Solid tumours
Development Tech	na